Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review

Alzheimer's Research and Therapy

Volumn 8, Issue 1, 2016, Pages 1-17

  Bemelmans, S A S A ^a   Tromp, K ^b   Bunnik, E M ^b   Milne, R J ^c   Badger, S ^c   Brayne, C ^c   Schermer, M H ^b   Richard, E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Alzheimer's disease; Behavioral effects; Biomarkers; Clinical research; Disclosure; Ethics; Prevention studies; Psychological effects; Risk; Social effects

Indexed keywords

APOENZYME; BIOLOGICAL MARKER; APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; ANXIETY; ARTICLE; BEHAVIOR; BEHAVIOR CHANGE; COGNITION; DEPRESSION; DISEASE ASSOCIATION; FAMILY HISTORY; FIRST-DEGREE RELATIVE; GENETIC RISK; GENOTYPE; HEALTH BEHAVIOR; HUMAN; INSURANCE; INTERPERSONAL COMMUNICATION; LONG TERM CARE; MEMORY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RESEARCH SUBJECT; RISK ASSESSMENT; SOCIAL ASPECT; SYSTEMATIC REVIEW; UNITED STATES; COGNITION DISORDERS; COMPLICATION; FACTUAL DATABASE; FEMALE; GENETICS; MALE; MEDICAL RESEARCH; METABOLISM; PSYCHOLOGY; PSYCHOTIC DISORDERS; SOCIAL BEHAVIOR; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BIOMARKERS; BIOMEDICAL RESEARCH; COGNITION DISORDERS; DATABASES, FACTUAL; DISCLOSURE; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; SOCIAL BEHAVIOR;

EID: 84994496503     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-016-0212-z     Document Type: Article

References (55)

1. Daviglus ML, Plassman BL, Pirzada A, Bell CC, Bowen PE, Burke JR, et al. Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol. 2011;68:1185-90.
2. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
3. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357-67.
4. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92.
5. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs13.
6. Ritchie CW, Molinuevo JL, Truyen L, Satlin A, Van der Geyten S, Lovestone S, et al. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. Lancet Psychiatry. 2016;3:179-86.
7. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119-28.
8. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275-83.
9. Cupples LA, Farrer LA, Sadovnick AD, Relkin N, Whitehouse P, Green RC. Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study. Genet Med. 2004;6:192-6.
10. Alzheimer Europe. http://www.alzheimer-europe.org/Research/Value-of-Knowing/Public-concerns-about-Alzheimer-s-disease. Accessed 24 Apr 2016.
11. Roberts JS, Connell CM. Illness representations among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord. 2000;14:129-36.
12. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469-75.
13. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349-56.
14. Grill JD, Johnson DK, Burns JM. Should we disclose amyloid imaging results to cognitively normal individuals? Neurodegener Dis Manag. 2013;3:43-51.
15. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509-17.
16. Mathis CA, Kuller LH, Klunk WE, Snitz BE, Price JC, Weissfeld LA, et al. In vivo assessment of amyloid-beta deposition in nondemented very elderly subjects. Ann Neurol. 2013;73:751-61.
17. Heshka JT, Palleschi C, Howley H, Wilson B, Wells PS. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med. 2008;10:19-32.
18. Rahman B, Meiser B, Sachdev P, Barlow-Stewart K, Otlowski M, Zilliacus E, et al. To know or not to know: an update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer disease risk. Genet Test Mol Biomarkers. 2012;16:935-42.
19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
20. Higgins JP, Altman DG, Gotzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
21. Critical Appraisal Skills Programme (CASP). http://www.casp-uk.net/checklists. Accessed 27 Jan 2016.
22. Chao S, Roberts JS, Marteau TM, Silliman R, Cupples LA, Green RC. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL study. Alzheimer Dis Assoc Disord. 2008;22:94-7.
23. Green RC, Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Brown T, et al. Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med. 2009;361:245-54.
24. Zick CD, Mathews CJ, Roberts JS, Cook-Deegan R, Pokorski RJ, Green RC. Genetic testing for Alzheimer's disease and its impact on insurance purchasing behavior. Health Aff (Millwood). 2005;24:483-90.
25. Gooding HC, Linnenbringer EL, Burack J, Roberts JS, Green RC, Biesecker BB. Genetic susceptibility testing for Alzheimer disease: motivation to obtain information and control as precursors to coping with increased risk. Patient Educ Couns. 2006;64:259-67.
26. Chilibeck G, Lock M, Sehdev M. Postgenomics, uncertain futures, and the familiarization of susceptibility genes. Soc Sci Med. 2011;72:1768-75.
27. Christensen KD, Roberts JS, Zikmund-Fisher BJ, Kardia SL, McBride CM, Linnenbringer E, et al. Associations between self-referral and health behavior responses to genetic risk information. Genome Med. 2015;7:10.
28. Caselli RJ, Langbaum J, Marchant GE, Lindor RA, Hunt KS, Henslin BR, et al. Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc. 2014;89:1389-96.
29. Green RC, Christensen KD, Cupples LA, Relkin NR, Whitehouse PJ, Royal CDM, et al. A randomized noninferiority trial of condensed protocols for genetic risk disclosure of Alzheimer's disease. Alzheimers Dement. 2014;11:1222-30.
30. Romero LJ, Garry PJ, Schuyler M, Bennahum DA, Qualls C, Ballinger L, et al. Emotional responses to APO E genotype disclosure for Alzheimer disease. J Genet Couns. 2005;14:141-50.
31. Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. The role of disease perceptions and results sharing in psychological adaptation after genetic susceptibility testing: the REVEAL study. Eur J Hum Genet. 2010;18:1296-301.
32. Lineweaver TT, Bondi MW, Galasko D, Salmon DP. Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. Am J Psychiatry. 2014;171:201-8.
33. Vernarelli JA, Roberts JS, Hiraki S, Chen CA, Cupples LA, Green RC. Effect of Alzheimer disease genetic risk disclosure on dietary supplement use. Am J Clin Nutr. 2010;91:1402-7.
34. Taylor DH, Cook-Deegan RM, Hiraki S, Roberts JS, Blazer DG, Green RC. Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Milwood). 2010;29:102-8.
35. Ashida S, Koehly LM, Roberts JS, Chen CA, Hiraki S, Green RC. Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. J Health Commun. 2009;14:768-84.
36. Arribas-Ayllon M. The ethics of disclosing genetic diagnosis for Alzheimer's disease: do we need a new paradigm? Br Med Bull. 2011;100:7-21.
37. LaRusse S, Roberts JS, Marteau TM, Katzen H. Genetic susceptibility testing versus family history-based risk assessment: Impact on perceived risk of Alzheimer disease. Genet Med. 2005;7:48-53.
38. Marteau TM, Roberts S, LaRusse S, Green RC. Predictive genetic testing for Alzheimer's diseases: Impact upon risk perception. Risk Anal. 2005;25:397-404.
39. Wells RE, Kaptchuk TJ. To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent. Am J Bioeth. 2012;12:22-9.
40. Symon A, Williams B, Adelasoye QA, Cheyne H. Nocebo and the potential harm of "high risk" labelling: a scoping review. J Adv Nurs. 2015;71:1518-29.
41. Cutler SJ, Hodgson LG. To test or not to test: interest in genetic testing for Alzheimer's disease among middle-aged adults. Am J Alzheimers Dis Other Demen. 2003;18:9-20.
42. Roberts JS. Anticipating response to predictive genetic testing for Alzheimer's disease: a survey of first-degree relatives. Gerontologist. 2000;40:43-52.
43. Roberts JS, LaRusse SA, Katzen H, Whitehouse PJ, Barber M, Post SG, et al. Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17:86-93.
44. Arias JJ, Karlawish J. Confidentiality in preclinical Alzheimer disease studies: when research and medical records meet. Neurology. 2014;82:725-9.
45. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 2002;287:3230-7.
46. Lloret A, Badia MC, Mora NJ, Pallardo FV, Alonso MD, Vina J. Vitamin E paradox in Alzheimer's disease: it does not prevent loss of cognition and may even be detrimental. J Alzheimers Dis. 2009;17:143-9.
47. Miller ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.
48. Roberts JS, Dunn LB, Rabinovici GD. Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. Neurodegener Dis Manag. 2013;3:219-29.
49. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9:1118-27.
50. Linnenbringer E, Roberts JS, Hiraki S, Cupples LA, Green RC. "I know what you told me, but this is what I think:" perceived risk of Alzheimer disease among individuals who accurately recall their genetics-based risk estimate. Genet Med. 2010;12:219-27.
51. Timmermans S, Buchbinder M. Patients-in-waiting: Living between sickness and health in the genomics era. J Health Soc Behav. 2010;51:408-23.
52. Wikler EM, Blendon RJ, Benson JM. Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. Alzheimers Res Ther. 2013;5:43.
53. Fanshawe TR, Prevost AT, Roberts JS, Green RC, Armstrong D, Marteau TM. Explaining behavior change after genetic testing: the problem of collinearity between test results and risk estimates. Genet Test. 2008;12:381-6.
54. Cassidy MR, Roberts JS, Bird TD, Steinbart EJ, Cupples LA, Chen CA, et al. Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. Alzheimers Dement. 2008;4:406-13.
55. Roberts JS, Cupples LA, Relkin NR, Whitehouse PJ, Green RC, Group RS. Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. J Geriatr Psychiatry Neurol. 2005;18:250-55.